Literature DB >> 11135381

Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study.

S C Radley1, C R Chapple, N P Bryan, D E Clarke, D A Craig.   

Abstract

The aim of the study was to evaluate the potential role for a selective alpha1-adrenoceptor agonist in the treatment of urinary stress incontinence. A randomised, double-blind, placebo-controlled, crossover study design was employed. Half log incremental doses of intravenous methoxamine or placebo (saline) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure (MUP), blood pressure, heart rate, and symptomatic side effects. Methoxamine evoked non-significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage. Systemic side effects including piloerection, headache, and cold extremities were experienced in all subjects. The results indicate that the clinical usefulness of direct, peripherally acting sub-type-selective alpha1-adrenoceptor agonists in the medical treatment of stress incontinence may be limited by associated piloerection and cardiovascular side effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135381     DOI: 10.1002/1520-6777(2001)20:1<43::aid-nau6>3.0.co;2-f

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  10 in total

1.  Advances in the understanding of sress urinary incontinence and the promise of stem-cell therapy.

Authors:  Akira Furuta; Lesley K Carr; Naoki Yoshimura; Michael B Chancellor
Journal:  Rev Urol       Date:  2007

Review 2.  Dilemmas in the management of female stress incontinence: the role of pelvic floor muscle training.

Authors:  Hatzimouratidis Konstantinos; Konstantinidou Eleni; Hatzichristou Dimitrios
Journal:  Int Urol Nephrol       Date:  2006-11-29       Impact factor: 2.370

Review 3.  Treatment of stress urinary incontinence: recent developments in the role of urethral injection.

Authors:  Philip van Kerrebroeck; Flip ter Meulen; Elisabeth Farrelly; Gregor Larsson; Lena Edwall; Aino Fianu-Jonasson
Journal:  Urol Res       Date:  2003-01-30

4.  Effect of alfuzosin on female primary bladder neck obstruction.

Authors:  A Athanasopoulos; K Gyftopoulos; K Giannitsas; P Perimenis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-11-04

Review 5.  Pharmacotherapy for stress urinary incontinence : present and future options.

Authors:  Norman R Zinner; Stephanie C Koke; Lars Viktrup
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Adrenergic drugs for urinary incontinence in adults.

Authors:  A Alhasso; C M A Glazener; R Pickard; J N'dow
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

7.  Swimming: effects on stress urinary incontinence and the expression of nerve growth factor in rats following transabdominal urethrolysis.

Authors:  Il Gyu Ko; Sung Eun Kim; Bo Kyun Kim; Mal Soon Shin; Chang Ju Kim; Sung Jin Yim; Yu Jeong Bang; In Ho Choi; Khae Hawn Kim
Journal:  Int Neurourol J       Date:  2011-06-30       Impact factor: 2.835

Review 8.  Stem cells for stress urinary incontinence: the adipose promise.

Authors:  Régis Roche; Franck Festy; Xavier Fritel
Journal:  J Cell Mol Med       Date:  2009-10-03       Impact factor: 5.310

9.  Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats.

Authors:  Ivan Jandric; Hrvoje Vrcic; Marica Jandric Balen; Danijela Kolenc; Luka Brcic; Bozo Radic; Domagoj Drmic; Sven Seiwerth; Predrag Sikiric
Journal:  Med Sci Monit Basic Res       Date:  2013-03-12

Review 10.  Cell Therapy Clinical Trials for Stress Urinary Incontinence: Current Status and Perspectives.

Authors:  Isabel María Aragón; Bernardo Herrera Imbroda; María Fernanda Lara
Journal:  Int J Med Sci       Date:  2018-01-01       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.